Siegel CA - Search Results

1

Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy.

Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, Sands BE. Johnson FR, et al. Among authors: siegel ca. Gastroenterology. 2007 Sep;133(3):769-79. doi: 10.1053/j.gastro.2007.04.075. Epub 2007 May 3. Gastroenterology. 2007. PMID: 17628557

2

Review article: practical management of inflammatory bowel disease patients taking immunomodulators.

Siegel CA, Sands BE. Siegel CA, et al. Aliment Pharmacol Ther. 2005 Jul 1;22(1):1-16. doi: 10.1111/j.1365-2036.2005.02520.x. Aliment Pharmacol Ther. 2005. PMID: 15963074 Review.

3

Risk factors for colorectal cancer in Crohn's colitis: a case-control study.

Siegel CA, Sands BE. Siegel CA, et al. Inflamm Bowel Dis. 2006 Jun;12(6):491-6. doi: 10.1097/00054725-200606000-00008. Inflamm Bowel Dis. 2006. PMID: 16775493

4

Risks and benefits of infliximab for the treatment of Crohn's disease.

Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Siegel CA, et al. Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976. doi: 10.1016/j.cgh.2006.05.020. Epub 2006 Jul 14. Clin Gastroenterol Hepatol. 2006. PMID: 16843733

5

Possible association between isotretinoin and inflammatory bowel disease.

Reddy D, Siegel CA, Sands BE, Kane S. Reddy D, et al. Among authors: siegel ca. Am J Gastroenterol. 2006 Jul;101(7):1569-73. doi: 10.1111/j.1572-0241.2006.00632.x. Am J Gastroenterol. 2006. PMID: 16863562

6

Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease.

Siegel CA, Levy LC, Mackenzie TA, Sands BE. Siegel CA, et al. Inflamm Bowel Dis. 2008 Jan;14(1):1-6. doi: 10.1002/ibd.20283. Inflamm Bowel Dis. 2008. PMID: 17924559

7

Are adult patients more tolerant of treatment risks than parents of juvenile patients?

Johnson FR, Ozdemir S, Mansfield C, Hass S, Siegel CA, Sands BE. Johnson FR, et al. Among authors: siegel ca. Risk Anal. 2009 Jan;29(1):121-36. doi: 10.1111/j.1539-6924.2008.01135.x. Epub 2008 Sep 26. Risk Anal. 2009. PMID: 18826414 Free PMC article.

8

Making therapeutic decisions in inflammatory bowel disease: the role of patients.

Siegel CA. Siegel CA. Curr Opin Gastroenterol. 2009 Jul;25(4):334-8. doi: 10.1097/MOG.0b013e32832b764b. Curr Opin Gastroenterol. 2009. PMID: 19417646 Free PMC article. Review.

9

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Siegel CA, et al. Clin Gastroenterol Hepatol. 2009 Aug;7(8):874-81. doi: 10.1016/j.cgh.2009.01.004. Epub 2009 Jan 24. Clin Gastroenterol Hepatol. 2009. PMID: 19558997 Free PMC article.

10

The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.

Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. Melmed GY, et al. Among authors: siegel ca. Clin Gastroenterol Hepatol. 2010 Aug;8(8):655-9. doi: 10.1016/j.cgh.2010.04.023. Epub 2010 May 6. Clin Gastroenterol Hepatol. 2010. PMID: 20451665

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters